Guggenheim initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $32 price target The firm says Caris is a precision diagnostics company offering clinical testing services in therapy selection indications and biopharma services through its assay menu and database. The company’s therapy selection platform and large database will continue to be “important differentiations from competitors and to drive long-term growth,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences initiated with an Overweight at JPMorgan
- Caris Life Sciences initiated with a Buy at BofA
- Caris Life Sciences initiated with a Buy at Guggenheim
- Caris Life Sciences: Strong Market Position and Growth Potential Justify Buy Rating
- Caris Life Sciences publishes Assure liquid biopsy platform study